Multiple Sclerosis
13 videos · last 6 months shuffled daily, then older videos newest first
▶
2:19 Major MS Trial Result: Ocrelizumab Protects Hand Function in Advanced PPMS
theMSguide reviews Ocrelizumab, the ORATORIO-HAND study and the results from the study.
▶
33:11 Multiple Sclerosis Breakthrough? Inside the Stem Cell Research That Could Transform MS Care
Dr. Flavia Nelson on regenerative stem cell therapy for aggressive, treatment-resistant multiple sclerosis, where the disease keeps progressing despite therapies that work for others.
▶
43:43 CAR-T Therapy in Neuroimmune Disease
Dr. Barbara Willekens of the University of Antwerp explains CAR-T cell therapy, why it is being explored in autoimmune disease including emerging trials in NMOSD and MOGAD, and how patients are selected for trials, for SRNA.
▶
30:58 CAR-T for NMOSD: A Phase 1 Trial
Dr. Michael Levy and Dr. Benjamin Greenberg describe for SRNA an autologous Phase 1 CAR-T study in aquaporin-4-positive NMOSD at Mass General and UT Southwestern, covering eligibility, risks and lessons for neuroimmune research.
▶
15:30 TAURUS 2 Trial Results: Magnetic Stimulation in MS
Natasha Stevens, Senior Program Manager of the MS Research Flagship at Menzies Institute for Medical Research, shares the results of the TAURUS 2 phase 2 trial of transcranial magnetic stimulation for treating multiple sclerosis.
▶
42:19 Multi-Site Neuroimaging Trials: Real-Time QC at Scale
Daniel Ontaneda, MD, PhD, of Cleveland Clinic explains in a QMENTA webinar how the 420-participant, multi-site CAVS-MS study used centralized imaging and rapid quality-control feedback to manage 750 site queries.
▶
30:56 Repurposed Drugs in Progressive MS Research
Ellen Mowry, Wee Yong and Laura Airas discuss International Progressive MS Alliance projects repurposing existing drugs: GLP-1 receptor agonists, salbutamol with ibudilast, and a hydroxychloroquine trial, for the MS International Federation.
▶
4:42 Phase I Trial on Safety and Feasibility of CAR-T in MS
Jeffrey Dunn, MD, Stanford University School of Medicine, Palo Alto, CA, shares findings on the safety and feasibility of CAR T-cell therapy for multiple sclerosis (MS) from a Phase I trial (NCT06138132).
▶
3:02 Multiple Sclerosis Clinical Trials and AI
Carmen Tur, MD, PhD, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain, discuses AI and MS in this video including applications such as selection of patients and designing outcomes.
▶
6:02 The AttackMS Clinical Trial Aims to Attack MS Early and Aggressively Using Tysarbi
Video from VJ Neurology looks at the AttackMS study, which aims to reduce the delay from diagnosis to treatment of individuals with multiple sclerosis (MS).
▶
9:40 Remyelination in MS Clinical Trials
Dominic from The MSGuide interviews Dr. Will Brown from University of Cambridge about current research into Remyelination in multiple sclerosis including a discussion of drug repurposing, current clinical trials at Addenbrookes hospital and a sense of how many years a marketed drug will be on the market.
▶
59:02 A Modern Approach to Multiple Sclerosis Trials Applying Innovative Digital Endpoint Solutions
A Clario webinar on applying digital endpoint solutions to multiple sclerosis clinical trials.
▶
4:39 Blinding by the Light: Multiple Sclerosis Clinical Trials
A video by a medical doctor looks at blinding in multiple sclerosis clinical trials.